[1] Amyloidosis is the most frequent cause of restrictive cardiomyopathy in the Western world. Unfortunately, this disease is generally misdiagnosed and its natural history and outcomes differ ...
Surprised? Recommendations From the World Heart Federation on Transthyretin Amyloid Cardiomyopathy The World Heart Federation published a detailed report on transthyretin amyloid cardiomyopathy ...
Everyday Health on MSN7mon
14 Questions to Ask Your Doctor About Transthyretin Amyloid CardiomyopathyIf you’ve been diagnosed with transthyretin amyloid cardiomyopathy (ATTR-CM), you probably have a lot of questions. For ...
an investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM). Vutrisiran is the generic name for AMVUTTRA, which is currently approved by ...
Vutrisiran is also in development for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM), which encompasses both wild-type and hereditary forms of the disease. Alnylam (Nasdaq ...
Expert Rev Cardiovasc Ther. 2010;8(7):1007-1113. Recurrence of amyloidosis in the cardiac allograft is a consideration in cardiac transplant. Amyloid deposit in the cardiac allograft was reported ...
an investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM). Vutrisiran is the generic name for AMVUTTRA ®, which is currently approved ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback